Skip to content

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00591825
Enrollment
54
Registered
2008-01-11
Start date
2006-03-31
Completion date
2012-12-31
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phobias

Brief summary

The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.

Detailed description

Exposure and Response Prevention (ERP) therapy has become the treatment of choice for specific phobias. ERP involves systematic and repeated exposure to a feared or anxiety-provoking stimulus, leading to habituation and extinction of the fear response. Animal models of fear extinction have shown that acute administration of D-cycloserine (DCS) prior to exposure to a feared stimulus enhances extinction of that fear. A recent study in human subjects with height phobia (a specific phobia) has also demonstrated that DCS facilitates the effects of ERP therapy. Current theories postulate that DCS facilitates fear extinction by enhancing the learning process and increasing consolidation of memories, but the neural mechanisms underlying this process are not understood. The proposed research aims to elucidate these mechanisms by using fMRI to measure brain activation during 1) symptom provocation and verbal learning two hours post-medication, and 2)repeated symptom provocation and verbal recognition one week post-medication. This research will also examine the effects of DCS on cognitive functioning using neuropsychological testing both two house and one week post-medication.

Interventions

DRUGD-cycloserine

D-cycloserine

DRUGPlacebo

Placebo

Sponsors

American Psychological Foundation
CollaboratorOTHER
American Psychological Association
CollaboratorUNKNOWN
University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Right-handed * Adults between 18 and 55 years of age * Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia. * Individuals of both genders and all races will be included

Exclusion criteria

* Women who are breastfeeding or pregnant * Individuals with medical conditions unsuitable for MR scanning * Individuals reporting a history of epilepsy or seizures * Individuals reporting an allergy to cycloserine * Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event * Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury \*Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia) * Individuals currently taking any psychotropic medication

Design outcomes

Primary

MeasureTime frameDescription
fMRI Brain Activations During Symptom Provocation2 WeeksRegions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.

Secondary

MeasureTime frameDescription
Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)2 WeeksThis scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.
Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)2 weeksThe RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.
Cognitive Functioning Measured Using the Iowa Gambling Test2 weeksThis test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will win them game money. However, sometimes cards result in losing game money. The task includes 100 trials and the total score represents the number of cards drawn from bad decks as compared to good or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.
Cognitive Functioning Measured Using the Wisconsin Card Sorting Task2 weeksThe Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.

Countries

United States

Participant flow

Participants by arm

ArmCount
Non-Phobic Control - Placebo
Participants without phobia given one administration of placebo.
14
Non-Phobic Control - DCS
Participants without phobia given one administration of 100 mg D-cycloserine (DCS).
13
Spider-phobic Placebo
Participants with phobia given one administration of placebo.
13
Spider-phobic DCS
Participants with phobia given one administration of 100 mg D-cycloserine (DCS).
14
Total54

Baseline characteristics

CharacteristicNon-Phobic Control - PlaceboNon-Phobic Control - DCSSpider-phobic PlaceboSpider-phobic DCSTotal
Age, Continuous23.09 years
STANDARD_DEVIATION 3.7
26.75 years
STANDARD_DEVIATION 9.09
26.00 years
STANDARD_DEVIATION 8.06
24.73 years
STANDARD_DEVIATION 6.65
25.65 years
STANDARD_DEVIATION 7.78
Sex: Female, Male
Female
10 Participants9 Participants7 Participants13 Participants39 Participants
Sex: Female, Male
Male
4 Participants4 Participants6 Participants1 Participants15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 140 / 130 / 130 / 13
other
Total, other adverse events
0 / 140 / 130 / 130 / 14
serious
Total, serious adverse events
0 / 140 / 130 / 130 / 14

Outcome results

Primary

fMRI Brain Activations During Symptom Provocation

Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.

Time frame: 2 Weeks

Population: There were 54 enrolled in the study. 8 subjects were excluded from fMRI analyses: 1 for claustrophobia, 3 for scanner artifact, 1 because of motion \>3mm; 3 of paradigm-consistent motion which could not be corrected for.

ArmMeasureGroupValue (MEAN)Dispersion
DCS PhobicfMRI Brain Activations During Symptom Provocationmid dorsal ACC Butterfly.022 percent signal changeStandard Deviation 0.114
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft hippocampus Butterfly.010 percent signal changeStandard Deviation 0.18
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight dlPFC Butterfly.150 percent signal changeStandard Deviation 0.203
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight dlPFC Spider.384 percent signal changeStandard Deviation 0.286
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft dlPFC Spider.250 percent signal changeStandard Deviation 0.183
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft hippocampus Spider.101 percent signal changeStandard Deviation 0.222
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft Insula Spider.200 percent signal changeStandard Deviation 0.182
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft dlPFC Butterfly.031 percent signal changeStandard Deviation 0.122
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight Insula Spider.107 percent signal changeStandard Deviation 0.19
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight hippocampus Spider.113 percent signal changeStandard Deviation 0.315
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft amygdala Butterfly.127 percent signal changeStandard Deviation 0.139
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight Insula Butterfly.017 percent signal changeStandard Deviation 0.144
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft Insula Butterfly.012 percent signal changeStandard Deviation 0.139
DCS PhobicfMRI Brain Activations During Symptom Provocationmid dorsal ACC Spider.242 percent signal changeStandard Deviation 0.135
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight amygdala Butterfly.082 percent signal changeStandard Deviation 0.157
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight hippocampus Butterfly.017 percent signal changeStandard Deviation 0.103
DCS PhobicfMRI Brain Activations During Symptom ProvocationRight amygdala Spider.241 percent signal changeStandard Deviation 0.157
DCS PhobicfMRI Brain Activations During Symptom ProvocationLeft amygdala Spider.322 percent signal changeStandard Deviation 0.182
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft dlPFC Butterfly.076 percent signal changeStandard Deviation 0.372
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft Insula Spider.157 percent signal changeStandard Deviation 0.373
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft Insula Butterfly.021 percent signal changeStandard Deviation 0.376
DCS ControlfMRI Brain Activations During Symptom ProvocationRight Insula Spider.174 percent signal changeStandard Deviation 0.287
DCS ControlfMRI Brain Activations During Symptom ProvocationRight Insula Butterfly.109 percent signal changeStandard Deviation 0.221
DCS ControlfMRI Brain Activations During Symptom Provocationmid dorsal ACC Spider.402 percent signal changeStandard Deviation 0.459
DCS ControlfMRI Brain Activations During Symptom Provocationmid dorsal ACC Butterfly.053 percent signal changeStandard Deviation 0.166
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft dlPFC Spider.122 percent signal changeStandard Deviation 0.361
DCS ControlfMRI Brain Activations During Symptom ProvocationRight dlPFC Spider.521 percent signal changeStandard Deviation 0.676
DCS ControlfMRI Brain Activations During Symptom ProvocationRight dlPFC Butterfly.431 percent signal changeStandard Deviation 0.585
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft amygdala Spider.202 percent signal changeStandard Deviation 0.308
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft amygdala Butterfly.149 percent signal changeStandard Deviation 0.137
DCS ControlfMRI Brain Activations During Symptom ProvocationRight amygdala Spider.155 percent signal changeStandard Deviation 0.347
DCS ControlfMRI Brain Activations During Symptom ProvocationRight amygdala Butterfly.181 percent signal changeStandard Deviation 0.244
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft hippocampus Spider.196 percent signal changeStandard Deviation 0.217
DCS ControlfMRI Brain Activations During Symptom ProvocationLeft hippocampus Butterfly.065 percent signal changeStandard Deviation 0.112
DCS ControlfMRI Brain Activations During Symptom ProvocationRight hippocampus Spider.310 percent signal changeStandard Deviation 0.224
DCS ControlfMRI Brain Activations During Symptom ProvocationRight hippocampus Butterfly.219 percent signal changeStandard Deviation 0.203
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight hippocampus Spider.075 percent signal changeStandard Deviation 0.193
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft Insula Spider-.013 percent signal changeStandard Deviation 0.167
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight amygdala Spider.183 percent signal changeStandard Deviation 0.336
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight hippocampus Butterfly.155 percent signal changeStandard Deviation 0.118
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft hippocampus Spider.185 percent signal changeStandard Deviation 0.184
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft amygdala Butterfly.254 percent signal changeStandard Deviation 0.157
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft Insula Butterfly.092 percent signal changeStandard Deviation 0.162
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft amygdala Spider.534 percent signal changeStandard Deviation 0.272
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight amygdala Butterfly.203 percent signal changeStandard Deviation 0.216
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft dlPFC Spider.019 percent signal changeStandard Deviation 0.118
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft dlPFC Butterfly.035 percent signal changeStandard Deviation 0.154
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight Insula Spider-.004 percent signal changeStandard Deviation 0.087
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight Insula Butterfly.133 percent signal changeStandard Deviation 0.139
Placebo PhobicfMRI Brain Activations During Symptom ProvocationLeft hippocampus Butterfly.204 percent signal changeStandard Deviation 0.17
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight dlPFC Spider.301 percent signal changeStandard Deviation 0.349
Placebo PhobicfMRI Brain Activations During Symptom Provocationmid dorsal ACC Butterfly.085 percent signal changeStandard Deviation 0.123
Placebo PhobicfMRI Brain Activations During Symptom Provocationmid dorsal ACC Spider.073 percent signal changeStandard Deviation 0.171
Placebo PhobicfMRI Brain Activations During Symptom ProvocationRight dlPFC Butterfly.249 percent signal changeStandard Deviation 0.42
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight Insula Spider.020 percent signal changeStandard Deviation 0.25
Placebo ControlfMRI Brain Activations During Symptom Provocationmid dorsal ACC Spider.071 percent signal changeStandard Deviation 0.18
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft Insula Spider.036 percent signal changeStandard Deviation 0.095
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft amygdala Spider.427 percent signal changeStandard Deviation 0.244
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft amygdala Butterfly.098 percent signal changeStandard Deviation 0.299
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight amygdala Spider.133 percent signal changeStandard Deviation 0.23
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight Insula Butterfly.017 percent signal changeStandard Deviation 0.211
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight hippocampus Spider.361 percent signal changeStandard Deviation 0.347
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight dlPFC Spider.038 percent signal changeStandard Deviation 0.464
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight dlPFC Butterfly.110 percent signal changeStandard Deviation 0.31
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight amygdala Butterfly-.017 percent signal changeStandard Deviation 0.273
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft Insula Butterfly.079 percent signal changeStandard Deviation 0.147
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft hippocampus Spider.131 percent signal changeStandard Deviation 0.206
Placebo ControlfMRI Brain Activations During Symptom ProvocationRight hippocampus Butterfly.329 percent signal changeStandard Deviation 0.283
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft dlPFC Spider.278 percent signal changeStandard Deviation 0.3
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft dlPFC Butterfly.075 percent signal changeStandard Deviation 0.435
Placebo ControlfMRI Brain Activations During Symptom Provocationmid dorsal ACC Butterfly-.059 percent signal changeStandard Deviation 0.244
Placebo ControlfMRI Brain Activations During Symptom ProvocationLeft hippocampus Butterfly.086 percent signal changeStandard Deviation 0.158
Secondary

Cognitive Functioning Measured Using the Iowa Gambling Test

This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will win them game money. However, sometimes cards result in losing game money. The task includes 100 trials and the total score represents the number of cards drawn from bad decks as compared to good or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
DCS PhobicCognitive Functioning Measured Using the Iowa Gambling Test44.29 units on a scaleStandard Deviation 23.68
DCS ControlCognitive Functioning Measured Using the Iowa Gambling Test32.62 units on a scaleStandard Deviation 26.76
Placebo PhobicCognitive Functioning Measured Using the Iowa Gambling Test28.58 units on a scaleStandard Deviation 21.89
Placebo ControlCognitive Functioning Measured Using the Iowa Gambling Test21.85 units on a scaleStandard Deviation 28.42
Secondary

Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)

The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.

Time frame: 2 weeks

ArmMeasureGroupValue (MEAN)Dispersion
DCS PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Organization4.93 units on a scaleStandard Deviation 1.33
DCS PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Copy34.68 units on a scaleStandard Deviation 2.49
DCS PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Delay26.08 units on a scaleStandard Deviation 3.81
DCS PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Immediate26.54 units on a scaleStandard Deviation 3.97
DCS ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Copy34.46 units on a scaleStandard Deviation 3.53
DCS ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Immediate24.77 units on a scaleStandard Deviation 6.66
DCS ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Delay23.35 units on a scaleStandard Deviation 7.11
DCS ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Organization4.92 units on a scaleStandard Deviation 1.55
Placebo PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Copy34.46 units on a scaleStandard Deviation 2.15
Placebo PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Immediate26.17 units on a scaleStandard Deviation 3.76
Placebo PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Organization3.69 units on a scaleStandard Deviation 1.97
Placebo PhobicCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Delay26.13 units on a scaleStandard Deviation 2.57
Placebo ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Immediate26.14 units on a scaleStandard Deviation 5.46
Placebo ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Organization4.14 units on a scaleStandard Deviation 1.96
Placebo ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Delay25.64 units on a scaleStandard Deviation 5.36
Placebo ControlCognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)Copy34.50 units on a scaleStandard Deviation 1.95
Secondary

Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)

This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.

Time frame: 2 Weeks

ArmMeasureGroupValue (MEAN)Dispersion
DCS PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 241.93 units on a scaleStandard Deviation 2.09
DCS PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 151.93 units on a scaleStandard Deviation 8.91
DCS PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 234.36 units on a scaleStandard Deviation 6.67
DCS PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 140.43 units on a scaleStandard Deviation 3.2
DCS ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 232.46 units on a scaleStandard Deviation 7.03
DCS ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 149 units on a scaleStandard Deviation 9.24
DCS ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 241.62 units on a scaleStandard Deviation 2.99
DCS ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 141.85 units on a scaleStandard Deviation 2.73
Placebo PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 234.85 units on a scaleStandard Deviation 8.21
Placebo PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 152.69 units on a scaleStandard Deviation 10.3
Placebo PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 141 units on a scaleStandard Deviation 4.28
Placebo PhobicCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 241.62 units on a scaleStandard Deviation 3.43
Placebo ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 142.07 units on a scaleStandard Deviation 3.83
Placebo ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 152.93 units on a scaleStandard Deviation 7.56
Placebo ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Logical Memory 235.43 units on a scaleStandard Deviation 5.2
Placebo ControlCognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)Faces 242.07 units on a scaleStandard Deviation 3.97
Secondary

Cognitive Functioning Measured Using the Wisconsin Card Sorting Task

The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.

Time frame: 2 weeks

Population: Two subjects did not complete the test because they had previous exposure to the test.

ArmMeasureValue (MEAN)Dispersion
DCS PhobicCognitive Functioning Measured Using the Wisconsin Card Sorting Task13.29 units on a scaleStandard Deviation 6.98
DCS ControlCognitive Functioning Measured Using the Wisconsin Card Sorting Task13.62 units on a scaleStandard Deviation 7.65
Placebo PhobicCognitive Functioning Measured Using the Wisconsin Card Sorting Task18.23 units on a scaleStandard Deviation 16.58
Placebo ControlCognitive Functioning Measured Using the Wisconsin Card Sorting Task15.67 units on a scaleStandard Deviation 9.33

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026